The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer.
 
Chia Jie Tan
Research Funding - AstraZeneca (Inst); GRAIL (Inst); SpringWorks Therapeutics (Inst)
 
Haopeng Liu
No Relationships to Disclose
 
Pegah Farrokhi
Research Funding - AstraZeneca (Inst)
 
Ignacio Garrido-Laguna
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals; Kanaph Therapeutics; OncXerna Therapeutics; SOTIO
Research Funding - 280 BIO (Inst); ABM (Inst); Bayer (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); EcoR1 Capital; GlaxoSmithKline (Inst); Guidepoint Inc; Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Pfizer (Inst); Quanta Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tango Therapeutics (Inst); Tolero Pharmaceuticals (Inst); Yingli Pharma (Inst)
 
David Stenehjem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Dracen; Iterion Therapeutics; Molecular Templates; Salarius Pharmaceuticals; SonaCare Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bioverativ (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)